Database / Liraglutide 3.0 mg
Liraglutide 3.0 mg
Saxenda · Novo Nordisk. The first-generation daily GLP-1 injection. Included as the historical baseline that newer drugs are measured against; it is not part of the rankings.
Average weight loss
8%
Stopped for side effects
9.9%
Trial length
56 wk
Ranking score
n/r
SCALE Obesity and Prediabetes results
Phase 3 · 56 weeks · 3.0 mg daily
Adults with obesity, no diabetes (n=3,731)
Weight loss
8.0%
Nausea
40.2%
Vomiting
16.3%
Diarrhea
20.9%
Constipation
20.0%
Quit due to side effects
9.9%
n/r = not reported. Counting everyone who started, weight loss was 8%. Placebo group: 2.6%.
Worth knowing
- Weight loss reported on an older intention-to-treat basis, which understates on-treatment results by a point or so.
–
Not ranked
Kept as a historical reference for older daily GLP-1 treatment. It is excluded from every ranking on this site.
At a glance
- Company
- Novo Nordisk
- Targets
- GLP-1
- Molecule
- Peptide
- Dosing
- Injection, daily
- Status
- FDA approved (Dec 2014)